Eli Lil­ly part­ner Ab­Cellera finds a CBO in the face of bam­lanivimab strug­gles; Fi­bro­Gen's next CSO walks in­to rox­adu­s­tat re­buff

→ Covid-19 vari­ants have marred the ef­fec­tive­ness of Eli Lil­ly and Ab­Cellera’s bam­lanivimab to such an ex­tent that the US gov­ern­ment stopped us­ing the mon­o­clon­al an­ti­body in March, fol­lowed by a sim­i­lar halt for the com­bo treat­ment with ete­se­vimab late last month. Ab­Cellera is nonethe­less press­ing on­ward with a new can­di­date for mild to mod­er­ate cas­es, LY-CoV1404, and this week Neil Berkley joined Carl Hansen’s squad as CBO. Berkley, a Glax­o­SmithK­line neu­ro­science vet­er­an, makes the leap from Halozyme, start­ing out at the San Diego biotech as head of on­col­o­gy glob­al part­ner­ing, cor­po­rate de­vel­op­ment in 2019 and earn­ing a pro­mo­tion to VP, head of busi­ness de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.